Haemonetics Corporation (NYSE:HAE) price is hovering lower on Tuesday, Apr 20, sinking -7.95% below its previous close.
A look at today’s price movement shows that the recent level at last check reads $74.68, with intraday deals fluctuating between $68.40 and $71.74. The company’s 5Y monthly beta was ticking 0.5 while its P/E ratio in the trailing 12-month period read 35.38. Taking into account the 52-week price action we note that the stock hit a 52-week high of $142.11 and 52-week low of $74.1. The stock lost -34.23% on its value in the past month.
Haemonetics Corporation, which has a market valuation of $3.85 Billion, is expected to release its quarterly earnings report May 03, 2021- May 07, 2021. The company stock has a Forward Dividend ratio of 0, while the dividend yield is 0. It is understandable that investor optimism is growing ahead of the company’s current quarter results. Analysts tracking HAE have forecast the quarterly EPS to grow by $0.69 per share this quarter, while the same analysts predict the annual EPS to hit $2.58 for the year 2021 and up to $3.53 for 2022. In this case, analysts estimate an annual EPS growth of -0.22% for the year and 0.37% for the next year.
On average, analysts have forecast the company’s revenue for the quarter will hit $222.98 Million, with the likely lows of $217Million and highs of $231.28 Million. The average estimate suggests sales growth for the quarter will likely fall by -6.5% when compared to those recorded in the same quarter in the last financial year. Staying with the analyst view, there is a consensus estimate of $868.83 Million for the company’s annual revenue in 2021. Per this projection, the revenue is forecast to drop -12.1% below that which the company brought in 2020.
On the technical perspective front, indicators give HAE a short term outlook of 50% Sell on average. Looking at the stock’s medium term indicators we note that it is averaging as a Hold, while an average of long term indicators are currently assigning the stock as 50% Sell.
Here is a look at the average analyst rating for the stock as represented on a scale of 1.00 to 5.00, with the extremes of 1.00 and 5.00 suggesting the stock is strong buy or strong sell respectively. Specifically, 7 analysts have assigned HAE a recommendation rating as follows: 1 rate it as a Hold; 5 advise Buy while 1 analyst(s) assign an Outperform rating. None analyst(s) have tagged the Haemonetics Corporation (HAE) stock as Underperform, with none recommending Sell. In general, analysts have rated the stock Buy, a scenario likely to bolster investors out for an opportunity to add to their holdings of the company’s shares.
If we dive deeper into the stock’s performance we see the positive picture represented by the PEG ratio, currently standing at 3.54. The overview shows that HAE’s price is at present -39.25% off the SMA20 and -43.29% from the SMA50. The Relative Strength Index (RSI) metric on the 14-day timeframe is pointing at 13.88, with weekly volatility standing at 6.99%. The indicator drops to 3.86% when calculated based on the past 30 days. Haemonetics Corporation (NYSE:HAE)’s beta value is holding at 0.5, while the average true range (ATR) indicator is currently reading 5.92. Considering analysts have assigned the stock a price target range of $108-$185 as the low and high respectively, we find the trailing 12-month average consensus price target to be $142.86. Based on this estimate, we see that today’s price at last check is roughly 57.09% off the estimated low and 169.09% off the forecast high. Investors will no doubt be excited to see the share price rise to $147, which is the median consensus price, and at that level HAE would be +113.82% from recent price.
Turning out attention to how the Haemonetics Corporation stock has performed in comparison to its peers in the industry, here’s what we find: HAE’s stock is -7.95% on the day and -30.58% in the past 12 months, while Abbott Laboratories (ABT) traded -4.08% in the latest session and is positioned +29.71% up on its price 12 months ago. Another comparison is with Medtronic Inc (MDT) whose stock price is up 1.42% in the current trading session, and has flourished +22.07% over the past year. Also, Stryker Corp (SYK) is currently showing downtrend of -7.95% while its price kept floating at -30.58% over the past year. As for Haemonetics Corporation, the P/E ratio stands at 35.38 lower than that of Abbott Laboratories’s at 49.51 and Medtronic Inc’s 59.69. Elsewhere in the market, the S&P 500 Index has fell -0.83% in today’s early trading, with the Dow Jones Industrial also seeing a negative session so far with -0.82%.
An analysis of the Haemonetics Corporation (NYSE:HAE) stock in terms of its daily trading volume indicates that the 3-month average is 514.41 Million. However, this figure declines on the past 10-day timeline to an average of 1.27 Million.
Current records show that the company has 50.82 Million in outstanding shares. According to data from Thomson Reuters, insiders’ percentage holdings are 0.6% of outstanding shares while the percentage share held by institutions stands at 99.57%. The stats also highlight that short interest as of March 30, 2021, stood at 1.58 Million shares, which puts the short ratio at the time at 3.79. From this we can glean that short interest is 3.11% of company’s current outstanding shares. Notably, we see that shares short in March rose slightly given the previous month’s figure stood at 1.04 Million. But the -37.11% downside, the stock’s price has registered year-to-date as of today’s value, will likely reignite investor interest given the prospect of it rallying higher ahead.